The type I interferon response in COVID-19: implications for treatment

Cited 17 time in webofscience Cited 0 time in scopus
  • Hit : 83
  • Download : 20
In this Comment, Jeong Seok Lee and Eui-Cheol Shin discuss contradictory results regarding the downregulation or upregulation of type I interferon responses in patients with COVID-19 and the implications for therapies that target this pathway. Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19.
Publisher
NATURE RESEARCH
Issue Date
2020-10
Language
English
Article Type
Editorial Material
Citation

NATURE REVIEWS IMMUNOLOGY, v.20, no.10, pp.585 - 586

ISSN
1474-1733
DOI
10.1038/s41577-020-00429-3
URI
http://hdl.handle.net/10203/276537
Appears in Collection
MSE-Journal Papers(저널논문)
Files in This Item
000559368200002.pdf(581.16 kB)Download
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 17 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0